Highlights Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-01-13 pm EST			5-day change	1st Jan Change
100.98 ^USD	+1.74%		+1.26%	+1.51%

01:30am	Merck & Co., Inc. Presents at 43rd Annual J.P. Morgan Healthcare Conference 2025, Jan-13-2025 04:30 PM
Jan. 13	GSK Acquiring US-Based IDRx for up to $1.15 Billion	MT

Highlights

GSK Acquiring US-Based IDRx for up to $1.15 Billion	Jan. 13	MT
Philips CEO sees subdued China sales this year	Jan. 13	RE
Leerink Partners Adjusts Price Target on Merck $119 From $136, Keeps Outperform Rating	Jan. 13	MT
Atropos Health, Inc. Collaborates with Merck for Rapid Evidence Generation to Accelerate Innovation for Life-Saving Treatments	Jan. 10	CI
IO Biotech Completes Enrollment in Phase 2 Trial of Cancer Vaccine to Treat Resectable Melanoma	Jan. 09	MT
UBS Cuts Price Target on Merck to $120 From $125, Maintains Buy Rating	Jan. 08	MT
Merck Says Gardasil HPV Vaccine Approved for Males in China	Jan. 08	MT
Merck?s GARDASIL® Receives Expanded Approval for Males in China	Jan. 08	CI
Truist Securities Downgrades Merck to Hold From Buy, Adjusts Price Target to $110 From $130	Jan. 08	MT
OPKO Health's ModeX Launches Phase 1 EBV Vaccine Candidate Trials With Merck	Jan. 07	MT
Merck Agrees to Acquire WuXi Biologics' Ireland Facility for $500 Million	Jan. 07	MT
WuXi Biologics to Sell Irish Vaccine Facility to Merck for $500 Million	Jan. 07	DJ
Drug Companies to Raise Prices on 250 Branded Drugs in 2025	Jan. 03	MT
Merck to Discontinue Zinplava for Clostridioides Difficile Infection	Dec. 24	MT
Merck: LM-299 antibody agreement finalized	Dec. 20	CF
Merck Closes Global License Deal for LM-299 with LaNova Medicines	Dec. 20	MT
Merck Closes Exclusive Global License Agreement for LM-299, an Investigational Anti-PD-1/VEGF Bispecific Antibody	Dec. 20	CI
BMO Capital Downgrades Merck & Co. to Market Perform From Outperform, Adjusts Price Target to $105 From $136	Dec. 20	MT
Personalis Rallies Following $50 Million Investment from Merck, Extended Agreement With Moderna	Dec. 19	MT
Merck: encouraging phase III results in HIV	Dec. 19	CF
Merck Buys $50 Million of Personalis Stock	Dec. 19	DJ
Merck Says Investigational HIV Therapy Meets Primary Efficacy, Safety Goals in Phase 3 Trials	Dec. 19	MT
Merck's HIV treatment meets main goal of two late-stage studies	Dec. 19	RE
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection	Dec. 19	CI
Sector Update: Health Care Stocks Softer in Late Afternoon Trading	Dec. 18	MT

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Highlights

Filters